顺铂植入剂经皮肝植入治疗肝癌的药动学研究

 目的 探讨顺铂植入剂在肝癌患者肿瘤部位植入后的药动学规律。 方法 B超引导下，用穿刺器械在肝癌患者瘤内多点穿刺植药；采集静脉血，石墨炉原子吸收法测定，测定结果进行加权处理、药动学模型拟合。 结果 顺铂植入剂在体内的过程为一室缓释模型，药动学方程是：ρ_t=A₁ e-Ke t+A₂e-Ka t+A₃e-Kr t ，血药达峰时间及峰浓度分别为110 h及0.35 mg·L-1，吸收、消除半衰期分别为2及300 h。 结论 此种给药方法的全身血循环药动学特点和参数，可为临床合理应用顺铂植入剂进行肝癌瘤内局部植入的间质化疗提供参考依据。

Pharmacokinetics of Cisplatin Implants with Percutaneous Liver Insertion in the Liver Cancer Therapy

OBJECTIVE To demonstrate pharmacokinetic properties of cisplatin implants in patients receiving percutaneous liver implantation for treating hepatocellular carcinoma. METHODS Under ultrasound-guided，multiple needle punctures were made and the insertion of cisplantin implants performed in the tumor. Venous blood samples with different intervals were collected accordingly. The samples were determined with graphite furnace atomic absorption spectrometry，and the obtained data were processed and described with the pharmacokinetic model. RESULTS The in vivo course of cisplatin implants was expressed as the one compartment model. The main pharmacokinetic parameters were as follows ρ_t =A₁e-Ke t+A₂e-Ka t+A₃ e-Kr t. The peak time t_max and corresponding peak concentration ρ_max of cisplatin were 110 h and 0.35 mg·L-1 ，respectively. The absorption half-life was 2 h，and the elimination half-life was 300 h. CONCLUSION This study results provide pharmacokinetic profile for the percutaneous liver insertion of cisplatin implants clinically for the interstitial chemotherapy.